Analysts' Top Healthcare Picks: DocGo (DCGO), Avidity Biosciences (RNA)
Stifel Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $6.5
Northland Securities Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $8
Northland Securities Sticks to Its Buy Rating for DocGo (DCGO)
DocGo Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on DocGo, Maintains $5 Price Target
Northland Securities Remains a Buy on DocGo (DCGO)
Buy Rating Affirmed for DocGo on Strong Quarterly Performance and Positive Growth Trajectory
Analysts Offer Insights on Healthcare Companies: Curaleaf Holdings (OtherCURLF) and DocGo (DCGO)
DocGo Price Target Maintained With a $7.00/Share by Needham
DocGo Analyst Ratings
Needham: Maintaining the DoCGO (DCGO.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $10.00 to $7.00.
DocGo Analyst Ratings
Cantor Fitzgerald Maintains Overweight on DocGo, Lowers Price Target to $5
Deutsche Bank Adjusts DocGo Price Target to $5 From $8.20, Maintains Buy Rating
DocGo (DCGO) Has a New Rating From Northland Securities
Analysts Are Bullish on Top Healthcare Stocks: DocGo (DCGO), Avadel Pharmaceuticals (AVDL)
Buy Rating on DocGo: Strong Growth Potential and Financial Health Despite Revenue Base Changes
DocGo Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), DocGo (DCGO) and Revvity (RVTY)